Tribun Health, a leading provider of digital pathology software, proudly announces its extraordinary win of the prestigious Best in KLAS award for Digital Pathology (Europe) for the third consecutive year in 2022, 2023, and 2024. This recognition underscores Tribun Health's unwavering commitment to excellence and innovation in the field of computational pathology.
Today, Owkin, a TechBio that combines the best of human and artificial intelligence to find the right treatment for every patient, announced it is working with Amazon Web Services (AWS) to transform drug discovery, de-risk and accelerate clinical trials, and develop AI diagnostics. Owkin will leverage AWS’s proven global infrastructure and secure, extensive and reliable cloud platform to enhance data operations, optimize for operational excellence, and drive forward research in precision medicine.
Paige deepens its AppLab's offerings by partnering with industry-leading third-party AI providers
Corista, a leader in digital pathology solutions, is excited to announce that it has received a Class II Medical Device License from Health Canada for its DP3 platform.
Join us for an enlightening webinar designed to showcase the integration and potential benefits of the Histolog Scanner in the realm of robot-assisted radical prostatectomy (RARP).
Deep Bio, a pioneer of AI-powered cancer diagnostics solutions, proudly announced the inclusion of DeepDx Prostate in CancerX's Solutions Catalog. This significant participation positions Deep Bio as a key contributor to CancerX's inaugural project, which is dedicated to dismantling barriers to digital innovation in oncology.
A mass that was attached to the underside of the tongue in an 8-year-old Pomeranian was noted on clinical examination by the primary veterinarian. This was surgically removed and sent for histopathological evaluation to NationWide Laboratories.
Diana Rosentul, a Regulatory Affairs Specialist at Aiosyn, intricately manages the regulatory landscape associated with the integration of AI-based solutions within clinical and research institutions. Drawing upon her extensive background in Medical Sciences and the regulation of Medical Devices, Diana discusses challenges linked to staying up-to-date and shares her insights on handling different regulatory policies concerning Aiosyn’s AI algorithms.
The 2025 Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) is set to take place in the vibrant city of Boston, Massachusetts, promising an engaging and transformative experience for all attendees.
In this webinar, we’ll introduce CRC Macrodissect AI, an advanced solution designed to assist in colorectal cancer tumor content scoring and selecting regions for downstream macrodissection. CRC Macrodissect AI provides objective and standardized scoring of tumor content and enhances precision and efficiency in tissue selection. Additionally, we’ll unveil the latest advancements in HER2 analysis, with our Breast HER2 AI product now incorporating HER2 low and ultralow classifications, addressing the growing need for more precise stratification in breast cancer research.
